CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca Pharmaceuticals LP v. Fresenius Kabi USA, LLC

1:17-cv-01795

Overview

Case Number 1:17-cv-01795
Filing Date 2017-12-14
Status Terminated
Termination Date 2018-01-22
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Movant

AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)

Represented By

5 Attorneys Listed

Lisa Barons Pensabene

O'Melveny & Myers LLP

Tel: +1 (212) 326-2077
Fax: +1 (212) 326-2061

7 Times Square, Times Square Tower, New York, NY 10036

Caitlin Hogan

Email: chogan@omm.com

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Defendant

AstraZeneca AB NPE (Individual / Inventor)

Represented By

4 Attorneys Listed

Lisa Barons Pensabene

O'Melveny & Myers LLP

Tel: +1 (212) 326-2077
Fax: +1 (212) 326-2061

7 Times Square, Times Square Tower, New York, NY 10036

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Fresenius Kabi USA, LLC Operating Company

Represented By

4 Attorneys Listed

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Imron T. Aly

Email: ialy@schiffhardin.com

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Plaintiff

AstraZeneca UK Limited NPE (University / Research)

Represented By

4 Attorneys Listed

Lisa Barons Pensabene

O'Melveny & Myers LLP

Tel: +1 (212) 326-2077
Fax: +1 (212) 326-2061

7 Times Square, Times Square Tower, New York, NY 10036

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 2 proceedings
🏛️
USPTO PTAB Trials 10 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US
Parallel Proceedings Across Jurisdictions (12 found):
PTAB: 10 U.S. Courts: 2
USPTO PTAB Trial 2017-08-04
IPR2017-01913

Fresenius Kabi USA, LLC v. AstraZeneca AB

U.S. Continuation Sibling (8329680)
Status: Institution Denied
USPTO PTAB Trial 2017-08-04
IPR2017-01912

FRESENIUS KABI USA, LLC v. AstraZeneca AB

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2017-08-04
IPR2017-01910

Fresenius Kabi USA,LLC v. AstraZeneca AB

U.S. Continuation Sibling (6774122)
Status: Institution Denied
USPTO PTAB Trial 2017-02-17
IPR2017-00905

InnoPharma Licensing LLC et al. v. AstraZeneca AB

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2017-02-17
IPR2017-00904

InnoPharma Licensing LLC et al. v. AstraZeneca AB

U.S. Continuation Sibling (6774122)
Status: Institution Denied
USPTO PTAB Trial 2017-02-17
IPR2017-00900

InnoPharma Licensing LLC et al. v. AstraZeneca AB

U.S. Continuation Sibling (8329680)
Status: Institution Denied
USPTO PTAB Trial 2016-06-29
IPR2016-01326

Mylan Pharmaceuticals Inc. v. AstraZeneca AB

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-06-29
IPR2016-01325

Mylan Pharmaceuticals Inc. et al. v. AstraZeneca AB et al.

U.S. Continuation Sibling (8329680)
Status: Institution Denied
USPTO PTAB Trial 2016-06-29
IPR2016-01324

Mylan Pharmaceuticals Inc. v. AstraZeneca AB

U.S. Continuation Sibling (7456160)
Status: Terminated-Settled
USPTO PTAB Trial 2016-06-29
IPR2016-01316

Mylan Pharmaceuticals Inc. v. AstraZeneca AB

U.S. Continuation Sibling (6774122)
Status: Terminated-Settled
U.S. District Court 2016-08-05
1:16-cv-00669

AstraZeneca Pharmaceuticals LP v. Mylan Institutional LLC

Asserted Patent
Status: DED
U.S. District Court 2014-06-03
1:14-cv-03547

ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC.

Asserted Patent
Status: NJD
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6774122
Formulation
Filed: 2001-01-09
Issued: 2004-08-10
Expired (Term Ended)
Expires: 2021-01-09
US7456160
Formulation
Filed: 2004-06-22
Issued: 2008-11-25
Expired (Term Ended)
Expires: 2023-06-01
US8329680
Formulation
Filed: 2008-10-15
Issued: 2012-12-11
Expired (Term Ended)
Expires: 2025-05-26
US8466139
Formulation
Filed: 2012-09-04
Issued: 2013-06-18
Active (5.8 yrs remaining)
Expires: 2032-09-04

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

2

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2 Motion to Dismiss 2

Key Dispositive Motions & Rulings

Motion to Dismiss Pending
***NOTE: If the parties jointly consent to Chief Magistrate Judge Thynges jurisdiction to conduct all proceedings in this case, then the Pretrial Conference and...
Entry #— • 2018-01-10
Motion to Dismiss Pending
***NOTE: If the parties jointly consent to Chief Magistrate Judge Thynges jurisdiction to conduct all proceedings in this case, then the Pretrial Conference and...
Entry #— • 2018-01-10
Procedural / Extension Motion Pending
SO ORDERED D.I. 14 STIPULATION TO EXTEND TIME Plaintiffs Shall Respond to Defendant's Counterclaims to February 5, 2018 filed by AstraZeneca UK Limited, AstraZe...
Entry #— • 2017-12-28
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME Plaintiffs Shall Respond to Defendant's Counterclaims to February 5, 2018 - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, ...
Entry #14 • 2017-12-22 Document →

Docket Entries

(38 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Fresenius Kabi USA, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2284691.) - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB, AstraZeneca UK Limited. (Attachments: # 1 Appendix A-E, # 2 Civil Cover Sheet)(fms) (Entered: 12/14/2017)

Entry #1 • 2017-12-14
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Fresenius Kabi USA, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2284691.) - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB, AstraZeneca UK Limited. (Attachments: # 1 Appendix A-E, # 2 Civil Cover Sheet)(fms) (Entered: 12/14/2017)

Entry #1 • 2017-12-14
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Fresenius Kabi USA, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2284691.) - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB, AstraZeneca UK Limited. (Attachments: # 1 Appendix A-E, # 2 Civil Cover Sheet)(fms) (Entered: 12/14/2017)

Entry #1 • 2017-12-14
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (fms) (Entered: 12/14/2017)

Entry #2 • 2017-12-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,774,122; 7,456,160; 8,329,680; 8,466,139. (fms) (Entered: 12/14/2017)

Entry #3 • 2017-12-14
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc